Switzerland
· Delayed Price · Currency is CHF Basilea Pharmaceutica AG Statistics
Total Valuation
Basilea Pharmaceutica AG has a market cap or net worth of CHF 552.12 million. The enterprise value is 601.60 million.
| Market Cap | 552.12M |
| Enterprise Value | 601.60M |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Basilea Pharmaceutica AG has 12.12 million shares outstanding. The number of shares has decreased by -17.17% in one year.
| Shares Outstanding | 12.12M |
| Shares Change (YoY) | -17.17% |
| Shares Change (QoQ) | -43.09% |
| Owned by Insiders (%) | 3.05% |
| Owned by Institutions (%) | 36.50% |
| Float | 11.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 14.47 |
| PS Ratio | 3.68 |
| PB Ratio | 32.89 |
| P/FCF Ratio | 59.14 |
| PEG Ratio | 0.51 |
Enterprise Valuation
| EV / Earnings | -922.70 |
| EV / Sales | 4.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 64.45 |
Financial Position
The company has a current ratio of 4.10, with a Debt / Equity ratio of 669.89.
| Current Ratio | 4.10 |
| Quick Ratio | 2.96 |
| Debt / Equity | 669.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | 12.05 |
| Interest Coverage | -0.87 |
Financial Efficiency
Return on equity (ROE) is -4.10% and return on invested capital (ROIC) is -2.73%.
| Return on Equity (ROE) | -4.10% |
| Return on Assets (ROA) | -2.05% |
| Return on Capital (ROIC) | -2.73% |
| Revenue Per Employee | 955,269 |
| Profits Per Employee | -4,179 |
| Employee Count | 147 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 4.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.64% in the last 52 weeks. The beta is 0.70, so Basilea Pharmaceutica AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -4.64% |
| 50-Day Moving Average | 41.33 |
| 200-Day Moving Average | 38.71 |
| Relative Strength Index (RSI) | 63.88 |
| Average Volume (20 Days) | 43,656 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Basilea Pharmaceutica AG had revenue of CHF 149.02 million and -652,000 in losses. Loss per share was -0.05.
| Revenue | 149.02M |
| Gross Profit | 24.12M |
| Operating Income | -6.86M |
| Pretax Income | -14.08M |
| Net Income | -652,000 |
| EBITDA | -5.60M |
| EBIT | -6.86M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 62.96 million in cash and 112.45 million in debt, giving a net cash position of -49.48 million or -4.08 per share.
| Cash & Cash Equivalents | 62.96M |
| Total Debt | 112.45M |
| Net Cash | -49.48M |
| Net Cash Per Share | -4.08 |
| Equity (Book Value) | 16.79M |
| Book Value Per Share | 1.38 |
| Working Capital | 117.23M |
Cash Flow
In the last 12 months, operating cash flow was 10.30 million and capital expenditures -966,000, giving a free cash flow of 9.34 million.
| Operating Cash Flow | 10.30M |
| Capital Expenditures | -966,000 |
| Free Cash Flow | 9.34M |
| FCF Per Share | 0.77 |
Margins
Gross margin is 16.19%, with operating and profit margins of -4.60% and -0.44%.
| Gross Margin | 16.19% |
| Operating Margin | -4.60% |
| Pretax Margin | -9.45% |
| Profit Margin | -0.44% |
| EBITDA Margin | -3.76% |
| EBIT Margin | -4.60% |
| FCF Margin | 6.26% |
Dividends & Yields
Basilea Pharmaceutica AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 17.17% |
| Shareholder Yield | 17.17% |
| Earnings Yield | -0.12% |
| FCF Yield | 1.69% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |